

Brighton and Sussex University Hospitals NHS Trust
Clinical Trials Delivery Performance Q2 2020 -2021

Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed	Maximum Number Of Patients Agreed	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial
17/LO/2058	231907	A PROSPECTIVE, MULTICENTER, NON-RANDOMIZED, POST-MARKET CLINICAL FOLLOW-UP STUDY TO CONFIRM SAFETY AND PERFORMANCE OF THE COHEREX WAVECREST® LEFT ATRIAL APPENDAGE OCCLUSION SYSTEM IN CURRENT MEDICAL PRACTICE IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION	Number Agreed	2	2	Date Agreed	28/02/2018	2	29/10/2019	2	Withdrawn By Host
17/EM/0371	229496	Strategic Management to Optimize Response To Cardiac Resynchronization Therapy. SMART CRT	Range Agreed	10	72	Date Agreed	20/10/2019	7	28/10/2019	7	Recruitment Finished
18/LO/0864	245423	A PHASE II, MULTICENTER, RANDOMIZED STUDY TO COMPARE THE EFFICACY OF VENETOCLAX PLUS FULVESTRANT VERSUS FULVESTRANT IN WOMEN WITH ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER WHO EXPERIENCED DISEASE RECURREN	Range Agreed	4	6	Date Agreed	30/09/2019	5	10/12/2019	8	Recruitment Finished
18/LO/0995	244737	A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Pembrolizumab Versus Treatment of Physician's Choice in Participants with Advanced Endometrial Cancer	Number Agreed	1	1	Date Agreed	31/01/2020	1	18/12/2019	1	Recruitment Finished
18/LO/2067	253346	Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy	Range Agreed	2	3	Date Agreed	31/12/2019	4	31/12/2019	4	Recruitment Finished
17/EM/0241	223736	Safety and efficacy analysis of FRED™/FRED™ Jr embolic device in aneurysm treatment	Range Agreed	5	10	Date Agreed	30/04/2019	3	31/12/2019	7	Recruitment Finished
15/LO/0928	170943	Mitral Valve Repair Clinical Trial (MAVERIC Trial)	Number Agreed	5	5	Date Agreed	31/03/2017	5	20/02/2020	5	Recruitment Finished
19/YH/0151	257273	B7981015 - PF-06651600 IN ADULT AND ADOLESCENT ALOPECIA AREATA (AA)	Number Agreed	4	4	Date Agreed	31/03/2020	8	01/03/2020	8	Recruitment Finished
19/LO/0496	259483	A Phase 3b Multicenter, Randomized, Double-Blind, Double-Dummy, Active Controlled Study Comparing the Safety and Efficacy of Upadacitinib to Dupilumab in Adult Subjects with Moderate to Severe Atopic Dermatitis.	Number Agreed	4	4	Date Agreed	01/03/2020	3	31/03/2020	3	Recruitment Finished
13/LO/1891	138192	MORE Response on Cardiac Resynchronization Therapy (CRT) with MultiPointPacing (MPP)	Number Agreed	15	15	Date Agreed	01/12/2016	20	13/12/2019	26	Recruitment Finished
17/SW/0255	234748	Clinical Trial Evaluation of the Percutaneous 4Tech TriCinch Coil Tricuspid Valve Repair System	Number Agreed	4	4	Date Agreed	31/08/2018	0	25/02/2020	4	Withdrawn By Sponsor
19/LO/1217	264929	Watchman FLX Left Atrial Appendage Closure Device Post Approval Study	Range Agreed	5	20	Date Agreed	01/11/2020	12	22/06/2020	12	Recruitment Finished
19/LO/1217	264929	Watchman FLX Left Atrial Appendage Closure Device Post Approval Study	Range Agreed	5	20	Date Agreed	01/11/2020	12	22/06/2020	12	Recruitment Finished
17/EM/0121	221773	A Study To InvestigateThe Safety, Tolerability And Efficacy Of Nebulised Curosurf® In Preterm Neonates With Respiratory Distress Syndrome (RDS)	Range Agreed	3	5	Date Agreed	31/12/2019	2	30/04/2020	3	Withdrawn By Sponsor
18/LO/1187	240011	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy	Number Agreed	3	3	Date Agreed	30/11/2019	5	13/05/2020	5	Recruitment Finished
19/EM/0034	255895	A multicentre, randomised, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of padsevonil as adjunctive treatment of focal-onset seizures in adult subjects with drug-resistant epilepsy	Number Agreed	2	2	Date Agreed	31/08/2020	3	22/05/2020	3	Withdrawn By Sponsor